Literature DB >> 1115064

Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels.

A B Weisse, C B Moschos, M J Frank, G E Levinson, J E Cannilla, T J Regan.   

Abstract

Patients with cor pulmonale and high hematocrit levels are often subjected to phlebotomy in the belief that the adverse effects of high viscosity may outweigh the benefit of increased oxygen carrying capacity. To evaluate this, 12 patients with stable cor pulmonale and hematocrit values greater than 55 per cent were studied before and after a series of venesections. Right heart and aortic pressures, cardiac output and blood gases were measured at three mean hematocrit levels, 61 per cent (stage I), 50 per cent (stage II) and 44 per cent (stage III), with blood volume unchanged. From stages I to II, there were significant decreases in both man pulmonary artery pressure and total pulmonary resistance. Oxygen transport fell but not oxygen consumption. Right ventricular end-diastolic pressure and cardiac output did not change. Right ventricular work either fell or was maintained by increased output. Frank-Starling performance (supine exercise) improved. No significant changes occurred with further reduction in hematocrit to normal levels (stage III). The findings of this study support the concept of overcompensating erythrocytosis in cor pulmonale, and the effects of moderate hematocrit reduction should not be overlooked in these severely ill patients.

Entities:  

Mesh:

Year:  1975        PMID: 1115064     DOI: 10.1016/0002-9343(75)90538-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

Review 1.  Investigation and Management of Erythrocytosis.

Authors:  Mary Frances McMullin
Journal:  Curr Hematol Malig Rep       Date:  2016-10       Impact factor: 3.952

2.  Treatment of pulmonary hypertension in chronic bronchitis and emphysema.

Authors:  P J Wallis; J A Wedzicha; D W Empey
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-05

Review 3.  Development of secondary polycythaemia in chronic airways obstruction.

Authors:  J R Stradling; D J Lane
Journal:  Thorax       Date:  1981-05       Impact factor: 9.139

4.  [Acute myocardial infarct caused by nicotine-induced erythrocytosis].

Authors:  S Andreas; K S Herrmann; H Kreuzer; V Wiegand
Journal:  Klin Wochenschr       Date:  1989-10-02

5.  Calf blood flow and oxygen carriage after reversal of polycythaemia secondary to hypoxic lung disease.

Authors:  P J Wallis; M C Apps; A C Newland; D W Empey
Journal:  Thorax       Date:  1986-04       Impact factor: 9.139

6.  Impact of pulmonary artery pressure on exercise function in severe COPD.

Authors:  Michael W Sims; David J Margolis; A Russell Localio; Reynold A Panettieri; Steven M Kawut; Jason D Christie
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

7.  Atrial natriuretic factor in chronic obstructive lung disease with pulmonary hypertension. Physiological correlates and response to peptide infusion.

Authors:  S Adnot; P Andrivet; P E Chabrier; J Piquet; P Plas; P Braquet; F Roudot-Thoraval; C Brun-Buisson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

Review 8.  Hypoxemia in patients with COPD: cause, effects, and disease progression.

Authors:  Brian D Kent; Patrick D Mitchell; Walter T McNicholas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-03-14

9.  The increase in pulmonary arterial pressure caused by hypoxia depends on iron status.

Authors:  Thomas G Smith; George M Balanos; Quentin P P Croft; Nick P Talbot; Keith L Dorrington; Peter J Ratcliffe; Peter A Robbins
Journal:  J Physiol       Date:  2008-10-27       Impact factor: 5.182

10.  Clinical iron deficiency disturbs normal human responses to hypoxia.

Authors:  Matthew C Frise; Hung-Yuan Cheng; Annabel H Nickol; M Kate Curtis; Karen A Pollard; David J Roberts; Peter J Ratcliffe; Keith L Dorrington; Peter A Robbins
Journal:  J Clin Invest       Date:  2016-05-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.